Know Cancer

or
forgot password

A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder and Ovarian Cancer


Phase 1
18 Years
N/A
Not Enrolling
Both
Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer

Thank you

Trial Information

A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder and Ovarian Cancer


Protocol CDX1307-02: CDX-1307 is an investigational drug that is being tested to see if it
can stimulate the immune system (the cells and substances that protect the body from
infection and foreign matter) of people with certain kinds of cancer. It is believed that
the body's immune system can attack tumor cells and kill them. It is thought that immune
cells recognize special proteins on the surface of tumors as a signal to fight the cancer.
One of these proteins is called human chorionic gonadotropin-beta (hCG-β) and is found on
several types of cancers including breast, colorectal, pancreatic, bladder and ovarian. The
study drug, CDX-1307, is given as an intravenous infusion (administered in a vein in the arm
or through a port-a-catheter). In addition, the study includes combination therapies which
are thought to stimulate the immune response against tumor cells. In addition, the study
includes combination therapies which are thought to stimulate the immune response against
tumor cells.

Inclusion Criteria


Inclusion Criteria

1. Patients must have incurable, metastatic or unresectable locally advanced breast,
colorectal, pancreatic, bladder or ovarian cancer with measurable or evaluable-only
disease. Locally advanced breast cancer is defined as inflammatory breast cancer with
biopsy-proven skin involvement, or chest wall recurrence. Locally advanced disease of
other histologies is defined according to the standard definition for that disease.
Evaluable-only disease includes bone only or unresectable skin/chest wall only
metastases, but does not include malignant effusion(s) only. Cancer with elevated
serum tumor marker(s) (e.g. CA27.29, carcinoembryonic antigen, etc.) only does not
constitute evaluable disease.

2. Patients must be 18 years of age or older.

3. Both genders may be enrolled.

4. At least 4 weeks must have elapsed between prior therapy and initiation of treatment
with CDX-1307. Prior radiation therapy must be completed at least 4 weeks prior to
enrollment. No prior radiopharmaceuticals within 8 weeks prior to enrollment. The
patient must have recovered from any clinically significant toxicity experienced
during prior treatment(s).

5. Patients on the following medications may be enrolled into the study if the
medications were initiated ≥ 8 weeks prior to Screening and if no dosing changes are
anticipated during the study:

1. Hormonal therapy including gonadotropin releasing hormone (GnRh) agonist,
antiandrogens, selective estrogen receptor modulators (SERMs), aromatase
inhibitors, and progestins.

2. Bisphosphonates.

6. Patients must have an ECOG Performance Status of 0 or 1.

7. Breast cancer patients must have received and progressed through at least one line of
chemotherapy or endocrine therapy for metastatic or unresectable locally advanced
breast cancer. Patients with HER2-positive breast cancer must have received and
progressed through at least one line of chemotherapy plus trastuzumab, or endocrine
therapy plus trastuzumab, for metastatic or unresectable locally advanced breast
cancer. For incurable colorectal, pancreatic, bladder, or ovarian cancer, where
therapy with potential survival benefit is available or where disease-specific
palliation is the goal of therapy, patients must have received these appropriate
standard of care therapies and experienced recurrence or progression while on that
care. If no such therapy is available, patients with progressive disease may be
enrolled. Chemotherapy or radiation must be discontinued at least 4 weeks prior to
initiation of vaccination with CDX-1307.

8. Patients must have a life expectancy ≥ 16 weeks.

9. Male patients who are sexually active must agree to practice an effective form of
barrier contraception during the course of the study.

10. Screening laboratory values must meet the following criteria:

- Neutrophils ≥1.5 x109/L

- Platelets >100 x109/L

- Hemoglobin ≥10 g/dL

- Creatinine <2 mg/dL

- AST ≤2 X ULN

- Bilirubin ≤2 X ULN unless due to Gilbert's syndrome.

* Laboratory abnormalities attributed to liver involvement with cancer but
outside of the normal range will be allowed if they do not exceed the following
limits:

- AST ≤4 X ULN

Exclusion Criteria

1. Since treatment with CDX-1307 theoretically may cause permanent sterility, women of
childbearing potential will be excluded. Women who participate in this study must be
post-menopausal [absence of menses for at least 2 years or age >55] and/or surgically
incapable of bearing children.

2. Previous administration of hCG-β vaccine or therapy.

3. Concurrent treatment with immunosuppressive or immunomodulatory agents.

4. Positive tests for HIV, HBV or HCV.

5. Patients with systemic infection within 72 hours of registration that require
antibiotics or produce a fever > 101oF.

6. Patients with active central nervous system metastases, unless previously treated and
asymptomatic and not progressive in size or number for 2 months (1 month in the case
of stereotactic radiation).

7. History of a second malignancy, except for adequately treated and cured basal or
squamous cell skin cancer or cervical cancer in situ; or any other cancer from which
the patient has been disease-free for ≥ 5 years.

8. History of anaphylactic reaction following exposure to humanized or human therapeutic
monoclonal antibodies, or known hypersensitivity to GM-CSF or yeast derived products.

9. Patients with any of the following conditions: myocardial infarction within 1 year of
Screening, congestive heart failure (unless LVEF ≥ 50% as determined by MUGA within
30 days of Screening), uncontrolled hypertension (≥ 160 mm Hg/systolic and ≥ 100 mm
Hg/diastolic), symptomatic or life-threatening arrhythmia persistent on medication at
Screening, or clinically evident chronic lung disease unless lung capacity ≥ 55% or
FEV1 ≥ 60% at Screening. Note that the performance of MUGA scans and Pulmonary
Function Tests are not required except if clinically indicated.

10. Any underlying medical condition that in the Principal Investigator's opinion will
make the administration of study drug hazardous to the patient or would obscure the
interpretation of adverse events.

11. Medical condition requiring the use of corticosteroids (must be discontinued at least
4 weeks prior to enrollment).

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To establish safety and tolerability profile of CDX1307 alone and with adjuvant in patients with breast, colorectal, pancreatic, bladder and ovarian cancer

Outcome Time Frame:

up to 2 years or until progression

Safety Issue:

Yes

Authority:

United States: Food and Drug Administration

Study ID:

CDX1307-02

NCT ID:

NCT00648102

Start Date:

January 2006

Completion Date:

December 2009

Related Keywords:

  • Breast Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Ovarian Cancer
  • Breast cancer
  • Colorectal cancer
  • Pancreatic cancer
  • Bladder cancer
  • Ovarian cancer
  • Metastatic cancer
  • Locally advanced cancer
  • Cancer Vaccine
  • Vaccine
  • Urinary Bladder Neoplasms
  • Breast Neoplasms
  • Colorectal Neoplasms
  • Ovarian Neoplasms
  • Pancreatic Neoplasms

Name

Location

Duke UniversityDurham, North Carolina  27710
Henry Ford Health SystemDetroit, Michigan  48202
Carolina BioOncology InstituteHuntersville, North Carolina  28078